Table of Contents
Metal-Based Drugs
Volume 2011, Article ID 763436, 10 pages
Research Article

Mutagenic Tests Confirm That New Acetylacetonate Pt(II) Complexes Induce Apoptosis in Cancer Cells Interacting with Nongenomic Biological Targets

Dipartimento di Scienze e Tecnologie Biologiche ed Ambientali, Università del Salento, Prov. le Lecce/Monteroni, 73100 Lecce, Italy

Received 30 July 2010; Revised 17 January 2011; Accepted 24 January 2011

Academic Editor: Giovanni Natile

Copyright © 2011 Sandra Angelica De Pascali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


New platinum(II) complexes [PtCl(O,O′-acac)(L)] (1) and [Pt(O,O′-acac)( 𝛾 -acac)(L)] (2) ( L = D M S O , a; DMS, b) containing a single chelated (O,O′-acac) (1), or one chelated and one 𝜎 -bonded ( 𝛾 -acac) acetylacetonate (2) have been synthesized. The new Pt(II) complexes exhibited high in vitro cytotoxicity on cisplatin sensitive and resistant cell lines and showed negligible reactivity with nucleobases (Guo and 5′-GMP) but selective substitution of DMSO/DMS with soft biological nucleophiles, such as L-methionine. In order to assess the ability of the new complexes with respect to cisplatin to induce apoptosis by interaction with nongenomic targets, the Ames' test, a standard reverse mutation assay, was carried out on two Salmonella typhimurium strains (TA98 and TA100). Interestingly, the new complexes did not show the well-known mutagenic activity exhibited by cisplatin and are, therefore, able to activate apoptotic pathways without interacting with DNA.